Understanding langerhans cell histiocytosis (LCH)

Langerhans Cell Histiocytosis (LCH) is a rare disorder marked by the excessive proliferation of Langerhans cells, a type of dendritic cell involved in immune responses. These cells normally play a role in detecting pathogens, but in LCH, they accumulate and form lesions in various organs, including the skin, bones, liver, and lungs. The condition exhibits a range of severity, from isolated lesions to multi-organ involvement, and can affect both children and adults.

AnyGenes offers specialized qPCR arrays that allow for in-depth profiling of key signaling pathways and gene expression patterns involved in Langerhans Cell Histiocytosis. Researchers can use these tools to analyze biomarkers associated with immune response, cell proliferation, and differentiation. By utilizing AnyGenes arrays, scientists gain a comprehensive understanding of the molecular underpinnings of LCH, leading to more precise diagnostics and the identification of potential therapeutic targets.

Discover our advanced qPCR arrays for Langerhans Cell Histiocytosis research.

LCH lesion composition. The composition of LCH lesions is very heterogenous with the presence of different components of the immune system. Crosstalk between the LCH cells and the infiltrating immune cells contributes to the formation of a highly inflammatory and dysfunctional microenvironment that inhibits the clearance of the LCH cells by the immune cells and favors their persistence and survival in the lesions.

Langerhans cell histiocytosis: causes and molecular pathways

The progression of LCH is closely tied to dysregulated signaling pathways. Key pathways such as the MAPK (Mitogen-Activated Protein Kinase) signaling pathway and RAF/MEK/ERK pathway have been found to be critical in the development of LCH. Mutations in genes like BRAF are often implicated, leading to abnormal cell growth and proliferation. Some of the other notable biomarkers: S100 protein, CD1a, Langerin (CD207) and CSF1R. The histological examination reveals characteristic features such as: Birbeck Granules and Granulomatous Infiltrates.

Symptoms and diagnosis of LCH

Symptoms of LCH can vary widely based on the organs affected:

Bone: Pain and swelling, often leading to fractures.
Skin: Rashes or lesions.
Endocrine System: Dysfunction may lead to conditions like diabetes insipidus.
Hematopoietic System: Cytopenias can occur if bone marrow is involved.
Lungs: Respiratory issues may arise from lung infiltration.

Clinical Evaluation: Assessment of symptoms like bone pain, skin lesions, or organ involvement.
Imaging Studies: X-rays, CT, and MRI scans identify bone and soft tissue lesions.
Biopsy: A tissue biopsy is crucial for a definitive diagnosis, revealing characteristic Langerhans cells.
Blood Tests: Lab tests assess organ function and detect inflammatory markers indicating disease activity.
Bone Marrow Biopsy: Used in systemic cases to evaluate disease extent.
Specialized Tests: Immunohistochemical staining and genetic testing help determine disease behavior and treatment options.

Immune response in LCH

The immune response in LCH is complex and involves various immune cell types:

T Cells: Elevated regulatory T lymphocytes (Tregs) in lesions suggest a role in suppressing anti-tumor immunity in disease progression.
Macrophages and Dendritic Cells: contribute to inflammation by releasing cytokines like TNF-α, which may promote LCH cell proliferation.
Cytotoxic Cells: CD8+ T cells and natural killer (NK) cells, though present, often have reduced effectiveness due to high levels of immunosuppressive factors.
Elevated Cytokines: Studies have shown significantly higher serum levels of soluble IL-2 receptor (sIL-2R), TNF-α, IL-10, and other inflammatory markers in patients with active disease compared to those with less severe forms.
Immunosuppressive Factors: Factors such as transforming growth factor-beta (TGF-β) may facilitate tumor cell survival and limit effective immune responses against LCH.

Therapeutics applications

Given the central role of the MAPK and PI3K-AKT pathways in LCH, these signaling cascades represent promising therapeutic targets. Inhibitors of BRAF, such as vemurafenib, have shown efficacy in treating LCH patients with the BRAF V600E mutation.

Other potential therapeutic targets include MEK inhibitors, which target downstream components of the MAPK pathway, and PI3K inhibitors. Combination therapies that target multiple pathways simultaneously are also being explored to improve treatment outcomes and reduce the likelihood of resistance.

Analyze your pathway data with AnyGenes® software

Scientific data is only as powerful as the analysis behind it.

AnyGenes® provides a dedicated data analysis tool specifically developed for SignArrays® pathway panels.

What does it allow you to do?

Automated ΔCq calculation
Normalization with selected housekeeping genes
Comparison of up to 10 experimental conditions
Generation of descriptive statistics
Publication-ready graphs
Exportable tables for manuscripts and presentations

Developed on Excel (compatible with 2007+), the software is user-friendly and requires no advanced bioinformatics skills.

Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file and send it at [email protected] to initiate your project.

Langerhans cell histiocytosis biomarker list

You can check the biomarker list included in this pathway, see below:

Species : Homo sapiens (human)

Human signaling pathways

Signaling Pathways	Product ref	Informations
Langerhans Cell Histiocytosis	LCH1H1	Download biomarker list
Langerhans Cell Histiocytosis	LCH2H1	Download biomarker list

Species : Mus musculus (mouse)

Mouse signaling pathways

Signaling Pathways	Product ref	Informations
Langerhans Cell Histiocytosis	LCH1M1	Download biomarker list

Species : Rattus norvegicus (rat)

Rat Langerhans Cell Histiocytosis

Signaling Pathways	Product ref	Informations
Langerhans Cell Histiocytosis	*******	Biomarker list in progress.

Species : Sus Scrofa (Pig)

Pig signaling pathways

Signaling Pathways	Product ref	Informations
Langerhans Cell Histiocytosis	*******	Biomarker list in progress.

Looking for more answers? Visit our Help & FAQ section to find detailed informations about our products, services, and technical support.

Bibliography

1. Sconocchia T, et al. Langerhans cell histiocytosis: current advances in molecular pathogenesis. Front Immunol. (2023)26;14:1275085.

2. Lin J, et al. Detection of Immune Microenvironment Changes and Immune-Related Regulators in Langerhans Cell Histiocytosis Bone Metastasis. Biomed Res Int. (2023)19;2023:1447435.

3. Mitchell J, et al. Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions. Front Pediatr. (2022)29:10:872859.

4. Feng C, et al. Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators. Front Oncol. (2021)7;11:631682.

5. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. (2020)16;135(16):1319-1331.

6. Allen CE, et al. Langerhans-Cell Histiocytosis. N Engl J Med. (2018)30;379(9):856–868.

Need pricing information or distributor details?
For quotations, product information, or project discussions, please contact our team at [email protected].